68-Ga FAPI 46
Alternative Names: 68Ga-FAPi-46; [68Ga]FAPI-46Latest Information Update: 28 Mar 2024
At a glance
- Originator University of Heidelberg
- Developer SOFIE; University of California
- Class Antineoplastics; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I Cholangiocarcinoma; Gastric cancer; Ovarian cancer
- Phase 0 Interstitial lung diseases
- No development reported Breast cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis, Newly diagnosed) in Azerbaijan (IV)
- 13 Oct 2023 68 Ga FAPI 46 licensed to GE HealthCare worldwide
- 13 Jun 2023 Aalborg University Hospital plans a phase II trial for Gastric Cancer and Oesophageal cancer (Diagnosis) in September 2023 (NCT05898854)